---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001058"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:36:20.340153+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q4 ORLADEYO revenue $70.7M; FY 2022 revenue $270.8M; 2023 guidance ≥$320M

## Summary
- ORLADEYO net revenue $70.7M in Q4 2022, $251.6M for FY 2022; 2023 guidance no less than $320M.
- Total Q4 revenue $79.5M (+68% YoY); net loss $71.5M ($0.38/share) vs $17.8M ($0.10) in Q4 2021 (incl. $55.8M gain).
- Full year net loss $247.1M ($1.33/share) vs $184.1M ($1.03) in 2021; cash $443.9M at Dec 31, 2022.
- Complement inhibitor program delayed due to nonclinical study observations; BCX10013 phase 1 showed >97% AP suppression.
- ORLADEYO peak sales expected $1B; Canadian positive reimbursement recommendation received.

## SEC filing metadata
- accession: 0001171843-23-001058
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/0001171843-23-001058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/f8k_022123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001058
- JSON: https://secwatch.observer/filing/0001171843-23-001058.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001058.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $79.5 million, net income $71.5 million, or $0.38 per share, EPS $0.38 per share. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $79.5 million
  - Net income: $71.5 million, or $0.38 per share
  - EPS: $0.38 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: molecules targeting C2, which are currently in lead optimization. Fourth Quarter 2022 Financial Results For the three months ended December 31, 2022, total revenues were $79.5 million, compared to $47.2 million in the fourth quarter of 2021 (+68 percent year-over-year). The increase was primarily due to $70.7 million in ORLADEYO net revenue in the fourth
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/0001171843-23-001058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.